Design, Setting, and Participants
prostate cancer, Cancer
SECONDARY, PROSTATE CANCER, CANCER
This secondary analysis of a randomized clinical trial was a secondary analysis of the Dana-Farber Cancer Institute 05-043 trial and included 350 patients with nonmetastatic unfavorable risk prostate cancer (PC).